



RECEIVED
DEC 11 2002 #9,
TECH CENTER 1600/2900 *Dec 12/12/02*

PATENT APPLICATION
SERIAL NO.: 10/038,279
ATTORNEY DOCKET NO.: 4029-012233

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit 1632 :

In re patent application of :

Luc SCHOONJANS et al. : **CONDITIONED CULTURE
MEDIA**

Serial No. 10/038,279 :

Filed January 4, 2002 :

Examiner- *Not yet assigned* :

Pittsburgh, Pennsylvania
December 3, 2002

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to the requirements of 37 C.F.R. §§ 1.56 and 1.97-1.98. Applicant submits this Supplemental Information Disclosure Statement along with the attached Form PTO/SB/08A (formerly PTO-1449). The references listed on Form PTO/SB/08A were cited in a related patent application.

Pursuant to 37 C.F.R. §1.97(b)(3), no fee is believed to be due for the

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231 on December 3, 2002

Linda C. Seger
(Name of Representative)

Linda C. Seger
Signature

12/03/2002
Date


submission of this Supplemental Information Disclosure Statement, as it is being submitted before the mailing date of a first Office Action on the merits. Nevertheless, the Commissioner for Patents is hereby authorized to charge any fees which may be required to Deposit Account No. 23-0650.

An original and two (2) copies of this Supplemental Information Disclosure Statement are enclosed.

Respectfully submitted,

WEBB ZIESENHEIM LOGSDON
ORKIN & HANSON, P.C.

By



Barbara E. Johnson
Registration No. 31,198
Attorney for Applicants
700 Koppers Building
436 Seventh Avenue
Pittsburgh, PA 15219-1818
Telephone: (412) 471-8815
Facsimile: (412) 471-4094
E-mail: WebbLaw@WebbLaw.com

{W0031932.1}



Please type a plus sign (+) inside this box → ☒

Approved for use through 10/31/2001. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/038,270
Sheet 2 of 2		Filing Date	January 4, 2002
		First Named Inventor	SCHOONJANS
		Group Art Unit	1632
		Examiner Name	Theresa Frederick
		Attorney Docket Number	4029-012233
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cite and/or country where published.	T ²
	1 ✓	E.D. Rosen et al., <i>Mice lacking factor VII develop normally but suffer fatal perinatal bleeding</i> ; Nature, Vol. 390, 1997; 290-293	
	2	M. Dewerchin et al., <i>Generation and Characterization of Urokinase Receptor-deficient Mice</i> ; J. Clin. Invest. © The American Society for Clinical Investigation, Inc., Vol. 97, No. 3, 1996; 870-878	
	3	L.A. Galli-Taliadoros et al., <i>Gene knock-out technology: a methodological overview for the interested novice</i> ; Journal of Immunological Methods 181, 1995; 1-15	
	4	M.E. Donohue et al., <i>Targeted Disruption of Mouse Yin Yang 1 Transcription Factor Results in Peri-Implantation Lethality</i> , Molecular and Cellular Biology, Oct. 1999, 7237-7244	
	5	S. O'Gorman et al., <i>Recombinase-Mediated Gene Activation and Site-Specific Integration in Mammalian Cells</i> , Reports, March 15, 1999; 1351-1355	
	6	S. Gukushige et al., <i>Genomic targeting with a positive-selection lox integration vector allows highly reproducible gene expression in mammalian cells</i> , Proc. Natl. Acad. Sci. USA, Vol. 89, September 1992; 7905-7909	
	7	C.J. Yee et al., <i>Expression and Characterization of Biologically Active Human Hepatocyte Growth Factor (HGF) by Insect Cells Infected with HGF-Recombinant Baculovirus</i> , Biochemistry, 1993; 32, 7922-7931	
	8	K. Araki et al., <i>Targeted integration of DNA using mutant lox sites in embryonic stem cells</i> , Nucleic Acids Research, 1997, Vol. 25, No. 4; 868-872	
	9	E.B. Rucker, J.A. Piedrahita, <i>Cre-Mediated Recombination at the Murine Whey Acidic Protein (mWAP) Locus</i> , Molecular Reproduction and Development, 1997; 48:324-331	
	10	Y-Q Feng et al., <i>Site-specific Chromosomal Integration in Mammalian Cells: Highly Efficient CRE Recombinase-mediated Cassette Exchange</i> , J. Mol. Biol. (1999) 292, 779-785	
	11	J-L Liu et al., <i>Conditional Knockout of Mouse Insulin-Like Growth Factor-1 Gene Using the Cre/loxP System (44500)</i> , P.S.E.B.M., 2000; Vol 223:344-351	
	12	M. Kolot et al., <i>Site-specific recombination in mammalian cells expressing the Int recombinase of bacteriophage HK022</i> , Molecular Biology Reports 26: 207-213; 1999	
	13	B.E. Clausen et al., <i>Conditional gene targeting in macrophages and granulocytes using LysMcre mice</i> , Transgenic Research 8:265-277; 1999	
	14	K. Rajewsky et al., <i>Perspective Series: Molecular Medicine in Genetically Engineered Animals</i> , J. Clin. Invest., Vol. 98, No. 3; August 1996; 600-603	
Examiner Signature	Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231.

{W0031932.1}